EUVIMEDEUVIMED entdecken
Open Access

Cinacalcet Reverses Short QT Interval in Familial Hypocalciuric Hypercalcemia Type 1

Thomas Cuny iD, Pauline Romanet iD, Michelle Goldsworthy, Carole Guérin, Marie Wilkin, Philippe Roche iD, Frédéric Sebag iD, Lynn E van Summeren, Mark Stevenson iD, Sarah A Howles, Jean-Claude Deharo iD, Rajesh V Thakker iD und 1 weitere

The Journal of Clinical Endocrinology & Metabolism · 2024

DOI: 10.1210/clinem/dgad494 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Thomas Cuny und 12 weiteren Autor:innen. Beteiligte Einrichtung: Aix Marseille University, APHM, Marseille Medical Genetics, Inserm U1251, Hôpital de la Conception, Service d'Endocrinologie, Marseille, France. Hauptthemen laut MEDLINE: Hypercalcemia, Hyperparathyroidism. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Familial hypocalciuric hypercalcemia type 1 (FHH-1) defines an autosomal dominant disease, related to mutations in the CASR gene, with mild hypercalcemia in most cases. Cases of FHH-1 with a short QT interval have not been reported to date.

Objective

Three family members presented with FHH-1 and short QT interval (<360 ms), a condition that could lead to cardiac arrhythmias, and the effects of cinacalcet, an allosteric modulator of the CaSR, in rectifying the abnormal sensitivity of the mutant CaSR and in correcting the short QT interval were determined.

Methods

CASR mutational analysis was performed by next-generation sequencing and functional consequences of the identified CaSR variant (p.Ile555Thr), and effects of cinacalcet were assessed in HEK293 cells expressing wild-type and variant CaSRs. A cinacalcet test consisting of administration of 30 mg cinacalcet (8 Am) followed by measurement of serum calcium, phosphate, and parathyroid hormone every two hours for 8 hours. An electrocardiogram was performed 8 hours after cinacalcet administration.

Results

The CaSR variant (p.Ile555Thr) was confirmed in all 3 FHH-1 patients and was shown to be associated with a loss of function that was ameliorated by cinacalcet. Cinacalcet decreased parathyroid hormone by >50% within two hours, and decreases in serum calcium and increases in serum phosphate occurred within 8 hours, with rectification of the QT interval, which remained normal after 3 months of cinacalcet treatment.

Conclusion

Our results indicate that FHH-1 patients should be assessed for a short QT interval and a cinacalcet test used to select patients who are likely to benefit from this treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypercalcemiaHyperparathyroidismReceptors, Calcium-SensingPhosphatesCalciumParathyroid HormoneHEK293 CellsMutationHumansCinacalcet

Stichwörter der Autor:innen

CASRFHH-1QT intervalcinacalcethyperparathyroidism

Substanzen

CinacalcetCalciumParathyroid HormonePhosphatesReceptors, Calcium-Sensing

Autor:innen und Institutionen

  • Aix Marseille University, APHM, Marseille Medical Genetics, Inserm U1251, Hôpital de la Conception, Service d'Endocrinologie, Marseille, France.
  • Aix Marseille University, APHM, Marseille Medical Genetics, Inserm U1251, Hôpital de la Conception, Laboratoire de Biochimie et Biologie moléculaire, Marseille, France.
  • Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
  • Aix Marseille University, APHM, Hôpital de la Conception, Service de Chirurgie endocrinienne, Marseille, France.
  • Aix Marseille University, APHM, Hôpital de la Timone, Service de Cardiologie, MarseilleFrance.
  • Integrative Structural & Chemical Biology & HiTS Platform, Cancer Research Centre of Marseille, CNRS UMR7258, Marseille, France.

ORCID-Profile: Thomas Cuny, Pauline Romanet, Philippe Roche, Frédéric Sebag, Mark Stevenson, Jean-Claude Deharo, Rajesh V Thakker, David Taïeb

Förderung

  • Wellcome Trust

Zitieren

APA

Cuny, T., Romanet, P., Goldsworthy, M., Guérin, C., Wilkin, M., Roche, P., Sebag, F., van Summeren, L. E., Stevenson, M., Howles, S. A., Deharo, J. C., Thakker, R. V., & Taïeb, D. (2024). Cinacalcet Reverses Short QT Interval in Familial Hypocalciuric Hypercalcemia Type 1. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad494

Vancouver

Cuny T, Romanet P, Goldsworthy M, Guérin C, Wilkin M, Roche P, et al. Cinacalcet Reverses Short QT Interval in Familial Hypocalciuric Hypercalcemia Type 1. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgad494

BibTeX
@article{Cuny2024,
  author = {Cuny, Thomas and Romanet, Pauline and Goldsworthy, Michelle and Guérin, Carole and Wilkin, Marie and Roche, Philippe and Sebag, Frédéric and van Summeren, Lynn E and Stevenson, Mark and Howles, Sarah A and Deharo, Jean-Claude and Thakker, Rajesh V and Taïeb, David},
  title = {Cinacalcet Reverses Short QT Interval in Familial Hypocalciuric Hypercalcemia Type 1},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgad494}
}
Kostenlos starten →